Cipla Ltd updates on launch of generic version of Sensipar™

Cipla Ltd and its subsidiary Cipla USA, Inc., (hereafter referred to as "Cipla") announced a phased launch of generic cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) in the USA. The launch is a subject of ongoing litigation.

Cipla's cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) is AB-rated generic therapeutic equivalent version of Sensipar®, a branded drug marketed by Amgen, Inc. Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT} in adult patients with chronic kidney disease (CKD) on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Shares of CIPLA LTD. was last trading in BSE at Rs.548.55 as compared to the previous close of Rs. 551.65. The total number of shares traded during the day was 73547 in over 829 trades.

The stock hit an intraday high of Rs. 552 and intraday low of 546.75. The net turnover during the day was Rs. 40363911.

Source : Equity Bulls

Keywords